Health Care and Biotech
Alcidion’s IT Targets Hospital Efficiency
Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.
Dec 19 2016
Estia Health Beset By Uncertainty
Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.
Dec 13 2016
Rebound For Sirtex
Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.
Dec 13 2016
Sirtex Reaction Overdone
Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.
Dec 12 2016
Previous Stories
Heart Device Potential Makes HeartWare A Buy
Nov 12 2010
HeartWare is developing a device for treating heart failure and Southern Cross Equities rates the stock as a Speculative Buy.
ResMed Keeps The Good News Coming
Nov 01 2010
Quarterly earnings for ResMed were better than many in the market had expected, leading to increases to forecasts and continued positive views on the stock.
Technicals And Fundamentals Converge For Acrux
Oct 26 2010
RBS Morgans remains positive on the outlook for shares in biotech Acrux.
CSL Feels The Currency Pain
Oct 14 2010
The strong Aussie is wiping about 9% off CSL’s earnings but can the Octa recall make up for the difference?
A Temporary Boost For CSL
Sep 28 2010
Competitor Octapharma has been temporarily taken out of the European and US IVIG markets and while this could tighten the global market brokers see few lasting earnings benefits for CSL.
QRxPharma: The Next Australian Growth Stock?
Sep 15 2010
Southern Cross Equities has initiated coverage on QRxPharma with a Speculative Buy rating, seeing the group’s MoxDuo drug as a potential company maker.
MS Predicts Upgrades For Resources, Plus More On Media
Sep 09 2010
Morgan Stanley suggests Diversified Resources stocks are about to enjoy upgrades to market forecasts. Plus a rally for copper. Plus the latest views on media stocks in Australia.
ImpediMed’s US Contract A Sign Of Things To Come?
Aug 25 2010
Medical device technology group ImpediMed has signed a contract with a US managed care organisation and RBS Morgans expects more deals will follow, with positive implications for the share price.
Primary Out Of Favour
Aug 18 2010
Primary Health Care delivered a disappointing full year earnings result and despite cutting forecasts brokers continue to see earnings risk to the downside in FY11.
Phosphagenics Targets Fat Busting For A Payoff
Aug 12 2010
Phosphagenics is trying to develop an anti-fat drug delivered via the skin, which if successful would offer significant upside according to Southern Cross Equities.
